RemeGen’s RC88 shows promising results in Phase I/II study for advanced solid tumors
RemeGen Co., Ltd., a leader in biopharmaceutical innovation based in China, has unveiled promising results from its Phase I/II clinical study of RC88, a first-in-class ... Read More
RemeGen, Innovent Biologics to collaborate on clinical trials for combination therapies with ADCs
RemeGen, a commercial-stage Chinese biotechnology firm, and Innovent Biologics have announced their collaboration in a clinical research and supply agreement. This partnership focuses on conducting ... Read More